Ad hoc-Mitteilungen

4basebio UK Societas - Director/PDMR Shareholding

PR Newswire

26 February 2021

4basebio UK Societas

(the "Company")

Director’s Dealing

4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief executive officer, acquired 3,000 ordinary shares at an average price of 345 pence per share on behalf of persons closely associated with him.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio UK Societas

Heikki Lanckriet
+44 (0)1223 967 943
Nominated Adviser

Cairn Financial Advisers LLP

Jo Tuner / Sandy Jamieson
+44 (0)20 7213 0880

 
Broker

finnCap Ltd

Geoff Nash/Richard Chambers/Charlotte Sutcliffe
+44 (0)20 7220 0500

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Heikki Lanckriet
2 Reason for notification   
a. Position/Status Chief Executive Officer
b. Initial notification/

Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio UK Societas
b. LEI 2138005D5SAG8FIR6G91
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary Shares





ISIN: GB00BLD8ZL39
b. Nature of the transaction Acquisition of ordinary shares
c. Price(s) and volume(s)
Volume(s) Price (p)
  1. 1,000
  2. 1,000
  3. 1,000
345p

345p

345p
d. Aggregated information

 

- Aggregated Volume

- Price


-3,000

-345 pence per share
e. Date of the transaction 25/2/2021
f. Place of the transaction London Stock Exchange, AIM

""

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Quelle: PR Newswire